PRRUF
Price
$0.19
Change
-$0.02 (-9.52%)
Updated
May 29 closing price
Capitalization
223.44M
XFOR
Price
$3.48
Change
-$0.28 (-7.45%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
84.3M
Interact to see
Advertisement

PRRUF vs XFOR

Header iconPRRUF vs XFOR Comparison
Open Charts PRRUF vs XFORBanner chart's image
Immutep
Price$0.19
Change-$0.02 (-9.52%)
Volume$600
Capitalization223.44M
X4 Pharmaceuticals
Price$3.48
Change-$0.28 (-7.45%)
Volume$1.15K
Capitalization84.3M
PRRUF vs XFOR Comparison Chart in %
Loading...
PRRUF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XFOR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PRRUF vs. XFOR commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRRUF is a Hold and XFOR is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (PRRUF: $0.19 vs. XFOR: $3.76)
Brand notoriety: PRRUF and XFOR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRRUF: 100% vs. XFOR: 17%
Market capitalization -- PRRUF: $223.44M vs. XFOR: $84.3M
PRRUF [@Biotechnology] is valued at $223.44M. XFOR’s [@Biotechnology] market capitalization is $84.3M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRRUF’s FA Score shows that 0 FA rating(s) are green whileXFOR’s FA Score has 0 green FA rating(s).

  • PRRUF’s FA Score: 0 green, 5 red.
  • XFOR’s FA Score: 0 green, 5 red.
According to our system of comparison, XFOR is a better buy in the long-term than PRRUF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRRUF’s TA Score shows that 2 TA indicator(s) are bullish while XFOR’s TA Score has 4 bullish TA indicator(s).

  • PRRUF’s TA Score: 2 bullish, 0 bearish.
  • XFOR’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, PRRUF is a better buy in the short-term than XFOR.

Price Growth

PRRUF (@Biotechnology) experienced а 0.00% price change this week, while XFOR (@Biotechnology) price change was -4.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.83%. For the same industry, the average monthly price growth was +22.37%, and the average quarterly price growth was +32.94%.

Industries' Descriptions

@Biotechnology (+6.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRRUF($223M) has a higher market cap than XFOR($84.3M). PRRUF YTD gains are higher at: -4.879 vs. XFOR (-82.938). PRRUF has higher annual earnings (EBITDA): -43.83M vs. XFOR (-91.11M). PRRUF has more cash in the bank: 159M vs. XFOR (63M). PRRUF has less debt than XFOR: PRRUF (1.69M) vs XFOR (78M). XFOR has higher revenues than PRRUF: XFOR (32.8M) vs PRRUF (0).
PRRUFXFORPRRUF / XFOR
Capitalization223M84.3M265%
EBITDA-43.83M-91.11M48%
Gain YTD-4.879-82.9386%
P/E RatioN/A0.71-
Revenue032.8M-
Total Cash159M63M252%
Total Debt1.69M78M2%
FUNDAMENTALS RATINGS
PRRUF vs XFOR: Fundamental Ratings
PRRUF
XFOR
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
84100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
7439
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XFOR's Valuation (74) in the Biotechnology industry is in the same range as PRRUF (84) in the null industry. This means that XFOR’s stock grew similarly to PRRUF’s over the last 12 months.

PRRUF's Profit vs Risk Rating (84) in the null industry is in the same range as XFOR (100) in the Biotechnology industry. This means that PRRUF’s stock grew similarly to XFOR’s over the last 12 months.

PRRUF's SMR Rating (97) in the null industry is in the same range as XFOR (100) in the Biotechnology industry. This means that PRRUF’s stock grew similarly to XFOR’s over the last 12 months.

XFOR's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for PRRUF (74) in the null industry. This means that XFOR’s stock grew somewhat faster than PRRUF’s over the last 12 months.

XFOR's P/E Growth Rating (100) in the Biotechnology industry is in the same range as PRRUF (100) in the null industry. This means that XFOR’s stock grew similarly to PRRUF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRRUFXFOR
RSI
ODDS (%)
N/A
Bearish Trend 5 days ago
90%
Stochastic
ODDS (%)
N/A
Bearish Trend 5 days ago
85%
Momentum
ODDS (%)
N/A
Bullish Trend 5 days ago
86%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
52%
Bearish Trend 5 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
51%
Bullish Trend 5 days ago
82%
Advances
ODDS (%)
N/A
Bullish Trend 8 days ago
79%
Declines
ODDS (%)
N/A
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 5 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 6 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
PRRUF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XFOR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FHEIX17.250.09
+0.52%
Fidelity Advisor Real Estate I
TEMVX9.250.01
+0.11%
Nuveen Emerging Markets Eq W
GAMNX11.70-0.04
-0.34%
Gabelli Global Mini Mites AAA
MRGKX59.81-0.25
-0.42%
MFS Core Equity R6
IHSRX23.21-0.17
-0.73%
Hartford Small Company R3

PRRUF and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRRUF has been loosely correlated with IMMP. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PRRUF jumps, then IMMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRRUF
1D Price
Change %
PRRUF100%
N/A
IMMP - PRRUF
40%
Loosely correlated
-3.01%
SAVA - PRRUF
33%
Loosely correlated
-4.20%
ELTX - PRRUF
27%
Poorly correlated
+1.84%
CALC - PRRUF
27%
Poorly correlated
-1.10%
XFOR - PRRUF
25%
Poorly correlated
-8.86%
More

XFOR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XFOR has been loosely correlated with ABP. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if XFOR jumps, then ABP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XFOR
1D Price
Change %
XFOR100%
-8.86%
ABP - XFOR
50%
Loosely correlated
+0.57%
HOFBF - XFOR
35%
Loosely correlated
N/A
PTNTD - XFOR
34%
Loosely correlated
N/A
INM - XFOR
32%
Poorly correlated
+1.83%
ARCT - XFOR
31%
Poorly correlated
-1.68%
More